Thera-SAbDab

CAPLACIZUMAB

>   Structural Summary
TherapeuticCaplacizumab
TargetVWF
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGRTFSYNPMGWFRQAPGKGRELVAAISRTGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAAGVRAEDGRVRTLPSEYTFWGQGTQVTVSS
Light Chainna
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatNanobody
Isotypena
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)NFD
Recorded Developmental TechnologyNanobody Technology
INN Year Proposed2011
INN Year Recommended2012
Companies InvolvedAblynx
Conditions ApprovedThrombotic thrombocytopenic purpura
Conditions Activena
Conditions DiscontinuedThrombosis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]